.png?width=1360&height=468&name=Cell%202025%20Logo%20(White).png "Cell 2025 Logo (White)")
Connecting Leaders From Every Stage of the Value Chain to Drive Advanced Therapy Development & Novel Biologics Processing
Highlights of the Two-Day Event
11 - 12 November 2025 | London, UK
Join Cell 2025 — where next-gen cell culture, bioprocessing, and therapeutic innovation converge to accelerate the future of cell & gene therapies.
Step into the epicentre of advanced therapy innovation at Cell 2025, Oxford Global’s premier event for the cell culture and cell & gene therapy community. From discovery through to commercialisation, this is where science meets strategy—and game-changing ideas are born.
Spanning three powerhouse programmes, the event offers the ultimate platform to explore the entire value chain. Whether you’re scaling production, fast-tracking development, or pushing the boundaries of AI in manufacturing, this is where the next generation of therapies takes shape.
Cell Culture & Bioprocessing Programme — advancing stable, scalable, and high-performing cell systems through cutting-edge engineering, next-gen bioprocessing, and 3D culture innovations.
Advanced Therapy Development Programme — accelerating the path from scientific discovery to clinical impact with breakthrough gene & cell therapy research, robust analytics, and regulatory-ready strategies.
Cell & Gene Therapy Manufacturing Programme — enabling the next generation of therapies through intelligent manufacturing, integrated supply chains, and AI-enhanced production platforms.
Expect bold ideas, brilliant minds, and breakthrough technologies. With cutting-edge presentations, C-suite keynotes, investor spotlights, and curated showcases, Cell 2025 isn’t just a conference—it’s your gateway to the future of bioprocessing and cell & gene therapy.
Cross-Programme Highlights of the event:
HSC Gene Therapy For Severe Genetic Diseases - From Development, Manufacture To Commercialisation
by Bobby Gaspar, Co-Founder & Chief Executive Officer, Orchard Therapeutics
Bobby is a world-renowned scientist and physician and accomplished strategic and organizational leader with more than 25 years of experience in medicine and biotechnology. He is one of the principal scientific founders and current chief executive officer of Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe. Bobby has been a pioneer in gene therapy and the evolution of hematopoietic stem cell (HSC) gene therapy technology—including some of the first studies in patients with severe primary immune deficiencies—bringing it from some of the first studies in patients into late-stage clinical trials. His unparalleled expertise and deep relationships with key physicians and treatment centers around the world are integral to Orchard’s efforts to identify patients with metachromatic leukodystrophy (MLD) and other severe genetic conditions through targeted disease education, early diagnosis and comprehensive newborn screening.
Bobby was named to the inaugural TIME100 Health list in 2024, recognizing him as one of the world’s most influential individuals impacting human health. In addition to his role at Orchard, Bobby also serves as the chair of the board of directors at Eligo Biosciences, a privately-held biotech company expanding the scope of genetic medicines through gene-editing of the microbiome. He is also a venture partner at F-Prime, a global venture creation and investment firm with $4.5 billion under management.
Bobby is an honorary professor of pediatrics and immunology at the University College London (UCL) Great Ormond Street Institute of Child Health and has led multiple clinical trials that have shown that gene therapy can successfully correct the genetic defect in immune deficiencies. He studied medicine and surgery at Kings College in London before completing his Ph.D. at the UCL Great Ormond Street Institute of Child Health.
Dame Molly Stevens, John Black Professor of Bionanoscience, University of Oxford
Professor Dame Molly Stevens FREng FRS joined as the John Black Professor of Bionanoscience in April 2023 at the Institute of Biomedical Engineering and the Department of Physiology, Anatomy & Genetics, and Deputy Director of the Kavli Institute for Nanoscience Discovery. Professor Dame Stevens obtained her PhD at the University of Nottingham, did her postdoctoral research at the Massachusetts Institute of Technology, and led a highly interdisciplinary research programme at Imperial College London from 2004-2023 where she still holds a part-time position. Since 2015, she has also been part-time Professor of Biomaterials and Regenerative Medicine in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet, Sweden.
Professor Dame Stevens is an international leader in ground-breaking biosensing technologies, transformative regenerative medicine and advanced therapeutics approaches; has published extensively (over 400 papers and H-index over 100) in leading journals such as Science, Nature, Nature Nanotechnologyand Nature Materials; and was named a Clarivate Analytics Highly Cited Researcher in Cross-Field Research. She is a serial entrepreneur and has significant expertise and experience in commercialisation of devices, with numerous patents filed and 4 spin-out companies based on her research.
Professor Dame Stevens has won >40 awards, including the Novo Nordisk Award in 2023, the MRS Mid-Career Researcher Award in 2022, and the American Chemical Society Award in Colloid Chemistry in 2020. Professor Dame Stevens is a Fellow of 8 Professional Bodies, including the Royal Society (FRS) and Royal Academy of Engineering (FREng), and is also a Foreign Member of the National Academy of Engineering and an International Honorary Member of the American Academy of Arts and Sciences. Amongst many leadership roles, Professor Dame Stevens is Director of the UK Regenerative Medicine Hub for Acellular Smart Materials and Deputy Director of the EPSRC-Interdisciplinary Research Collaboration i-sense for biosensing.
Guiding the conversation at Cell 2025 is Erin Harris, Chief Editor of Cell & Gene and a leading voice in the advanced therapies space. With a deep understanding of the industry and a passion for amplifying impactful stories, Erin brings sharp insight, thoughtful perspective, and engaging energy to the stage. From panel discussions to fireside chats, she’ll be your go-to guide throughout the event—helping you navigate key sessions, spotlight emerging trends, and connect with the people shaping the future of cell and gene therapies.
Get up close and personal with industry trailblazers in our Fireside Chats - informal, candid conversations taking place on 11th November. Hear firsthand how leaders are tackling big challenges in implementing novel technologies such as AI/ML in drug discovery workflows, driving innovation, and shaping the future of drug development. Expect real stories, bold ideas, and valuable insights you won’t find in a typical presentation:
• Patient Advocacy & Patient Engagement
• CGT Development & Manufacturing
Wrap up Day 1 in style with our exclusive networking drinks reception—where the brightest minds in cell culture, bioprocessing & advanced therapy development come together to spark new ideas, forge powerful connections, and unwind in a vibrant atmosphere. Erin Harris, Chief Editor of Cell & Gene, will kick off the evening, setting the stage for a relaxing drinks reception charged with energy, inspiration, and opportunity. Grab a drink, mix, mingle, and let the conversations flow!
Don’t miss our exclusive cross-programme roundtables—taking place bright and early from 8:30 to 9:00am. Grab a coffee, pick up a pastry, and engage in dynamic, informal discussions led by advanced therapy experts on the most critical challenges and innovations shaping cell and gene therapy development. It’s your opportunity to ignite new ideas, explore cutting-edge solutions, and connect with peers before the day’s sessions begin.
- Market Access of AMPTs – Moderated by Panos Kefalas, Director of Access Strategy, Cell & Gene Therapy Catapult- Future Bullet Proof CAR-T Manufacturing – Moderated by Sarah Snykers, Senior Director of Operations, Legend Biotech
- Data Integrity – Moderated by Christopher Middendorf, Senior Director, Hogan Lovells & Sally Gu, Senior Associate, Hogan Lovells
- Tissue Engineering & Stem Cell Development
Discover the future of advanced therapies at Cell 2025’s Start-Up Zone—an exciting launchpad for 10+ pioneering start-ups at the forefront of cell culture, bioprocessing, and next-gen therapy development. Whether you’re pitching your breakthrough, demoing cutting-edge tech, or forging game-changing partnerships, this is your moment to shine. From IP strategy and supply chain readiness to investor insights and commercial potential, the Start-Up Zone is where breakthrough ideas gain the visibility, connections, and critical guidance they need to scale. It’s your opportunity to engage with seasoned experts, strategic partners, and forward-thinking investors ready to shape the future of advanced therapies with you.
As regulatory science races to keep pace with the rapid evolution of cell and gene therapies, Cell 2025 offers a vital platform to explore the latest guidance, global frameworks, and strategies for accelerating approval and patient access. Don’t miss a series of expert-led presentations and panel discussions that unpack this fast-moving landscape, including:
Panel Discussion: Navigating Global Regulatory Challenges in Cell & Gene Therapy – Sally Gu, Senior Associate, Hogan Lovells; François Gianelli, Chief Regulatory & Quality Officer, TreeFrog Therapeutics; Christopher Middendorf, Senior Director, Hogan Lovells
Gain practical insights into regulatory innovation, global alignment, and what it takes to bring CGTs to patients safely, swiftly, and successfully.
Cell Culture & Bioprocessing Programme:
- Panel Discussion: Novel Formats For Cell Line Engineering - Vincenzo Di Cerbo, Lead Scientist, Cell and Gene Therapy Catapult
- Panel Discussion: Streamlining Bioprocessing: Automation & Integration In Downstream Workflows - Parag Kumthekar, Gene Therapy Downstream Process Development Lead, UCB; Cristina Peixoto, Head Of Downstream Process Development Lab, iBET
- Panel Discussion: Overcoming The Challenges Of Moving From In Vivo, In Vitro To 3D Cell Models - Rhiannon David, Director, Advanced Cell Models / Microphysiological Systems, AstraZeneca; Aline Miller, Professor, University of Manchester; Maryna Panamarova, 3D Cellular Modelling Specialist, Cellular Operations, Wellcome Sanger Institute; Giacomo Domenici, Research Scientist, iBET
Advanced Therapy Development Programme:
- Panel Discussion: Experiences In Executing Cell & Gene Therapy Studies With Patient Engagement In Mind - Panteli Theocharous, Chief Therapeutics Officer & Head Of Medical & Scientific Affairs, Garuda Therapeutics; Terri Gaskell, Chief Technology Officer, Rinri Therapeutics; Joanna Brewer, Chief Scientific Officer, Adaptimmune; Nitin Patel, Vice President Of Late-Stage Clinical Development, Legend Biotech
- Presentation: Clinical Development Of Engineered TCR-T Therapies To Generate A Sarcoma Franchise - Joanna Brewer, Chief Scientific Officer, Adaptimmune
Cell & Gene Therapy Manufacturing Programme:
- Panel Discussion: Bridging The Gap Between R&D And Manufacturing For Digital & Automation Solutions - Tiffany Rau, Professor Biochemistry & Cell Biology, University College Cork; Daria Marsh, Head of Bioprocessing, Cell & Gene Catapult; Lydia Caro, Associate Director, Head Of Cell Sciences, Ichnos Sciences
- Presentation: Smart Manufacturing – Thorsten Gorba, Vice President Process & Analytical Development, Aspen Neuroscience
With 150+ speakers representing large pharmaceutical companies, emerging biotechs & renowned academic institutions, we are proud to welcome over 45 award-winning experts across the 2 programmes:
• Shadi Farhangrazi, Chief Executive Officer of S.M. Discovery Group, received the 2018 BioInnovation Award for her work in drug discovery
• Christoph Rösli, Director of Research Bern at CSL Behring, received the 2021 Swiss Biotech Success Stories Award for his contributions to biotechnology research.
• Vineeta Tripathi, Chief Executive Officer of Vitarka Therapeutics, received the 2019 Women in Bio Entrepreneurial Leadership Award for her work in biotech entrepreneurship
• Stephen Pham, Senior Vice President at Avalyn Pharma, was awarded the 2019 Respiratory Innovation Award
• Emma Mead, Chief Scientific Officer at Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford, was honoured with the 2020 Alzheimer's Research UK Young Investigator of the Year Award for her work in neurodegenerative disease research.
• Raul Rodriguez, Vice President at Woxsen University, received the 2021 Entrepreneur of the Year Award for his contributions to education in the biotech field.
• Philip Hewitt, Global Head of Early Investigative Toxicology at Merck, was honoured with the Society of Toxicology's 2018 Achievement Award for his significant impact in toxicological research.
.jpg?width=2819&height=1174&name=74dfee8e-75c7-46e0-9f51-31b709af2ede-2-5668375logo-Nanion_logo_black_RGB_300dpi-(2).jpg){kind=logo}
Join us on Day 2 the Visionary Voices stage for a powerful and thought-provoking panel celebrating the women transforming the future of cell and gene therapy. This dynamic session explores what it means to lead with impact—breaking down barriers, championing inclusive work environments, and empowering the next generation of scientific innovators. Hear from pioneering voices as they share personal stories, hard-won insights, and bold visions for a more equitable life sciences industry. Moderated by Erin Harris, Chief Editor from Cell & Gene.
Panellists: Cornel Chiriac, Investment Director, M&G Investments, Crossover Fund and Hassan Mahmudul, Investment Manager, UK Innovation & Science
What does it take to fund the next wave of breakthroughs in cell and gene therapy?
Join top investors and industry leaders for a candid discussion on navigating today’s complex investment landscape—from spotting emerging trends and high-potential hotspots to avoiding common red flags. Explore how companies can overcome funding bottlenecks in a competitive market and chart the right path toward scalable, sustainable CGT innovation. Whether you’re a start-up seeking capital or a stakeholder shaping the future of biotech investment, this session delivers the insights you need to stay ahead.
Connect and Network
Experience an event that celebrates meaningful, one-on-one connections in a dynamic, bustling atmosphere.
With Cell 2025, enjoy a vibrant crowd with the warmth of personal interactions and curated experiences